vs

Side-by-side financial comparison of Absci Corp (ABSI) and ICON PLC (ICLR). Click either name above to swap in a different company.

ICON PLC is the larger business by last-quarter revenue ($2.0B vs $650.0K, roughly 3142.8× Absci Corp). ICON PLC runs the higher net margin — 0.1% vs -4548.0%, a 4548.1% gap on every dollar of revenue. On growth, ICON PLC posted the faster year-over-year revenue change (0.6% vs -2.3%). ICON PLC produced more free cash flow last quarter ($333.9M vs $-29.3M). Over the past eight quarters, ICON PLC's revenue compounded faster (0.6% CAGR vs -14.9%).

Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.

ICON plc is an Irish headquartered multinational healthcare intelligence and clinical research organisation. As of February 2025 had approximately 41,900 employees in 55 countries.

ABSI vs ICLR — Head-to-Head

Bigger by revenue
ICLR
ICLR
3142.8× larger
ICLR
$2.0B
$650.0K
ABSI
Growing faster (revenue YoY)
ICLR
ICLR
+2.9% gap
ICLR
0.6%
-2.3%
ABSI
Higher net margin
ICLR
ICLR
4548.1% more per $
ICLR
0.1%
-4548.0%
ABSI
More free cash flow
ICLR
ICLR
$363.2M more FCF
ICLR
$333.9M
$-29.3M
ABSI
Faster 2-yr revenue CAGR
ICLR
ICLR
Annualised
ICLR
0.6%
-14.9%
ABSI

Income Statement — Q4 2025 vs Q3 2025

Metric
ABSI
ABSI
ICLR
ICLR
Revenue
$650.0K
$2.0B
Net Profit
$-29.6M
$2.4M
Gross Margin
Operating Margin
-4775.5%
4.2%
Net Margin
-4548.0%
0.1%
Revenue YoY
-2.3%
0.6%
Net Profit YoY
-2.0%
-98.8%
EPS (diluted)
$-0.19
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABSI
ABSI
ICLR
ICLR
Q4 25
$650.0K
Q3 25
$378.0K
$2.0B
Q2 25
$593.0K
$2.0B
Q1 25
$1.2M
$2.0B
Q4 24
$665.0K
Q3 24
$1.7M
$2.0B
Q2 24
$1.3M
$2.1B
Q1 24
$898.0K
$2.1B
Net Profit
ABSI
ABSI
ICLR
ICLR
Q4 25
$-29.6M
Q3 25
$-28.7M
$2.4M
Q2 25
$-30.6M
$183.0M
Q1 25
$-26.3M
$154.2M
Q4 24
$-29.0M
Q3 24
$-27.4M
$197.1M
Q2 24
$-24.8M
$146.9M
Q1 24
$-22.0M
$187.4M
Operating Margin
ABSI
ABSI
ICLR
ICLR
Q4 25
-4775.5%
Q3 25
-7977.2%
4.2%
Q2 25
-5293.9%
10.4%
Q1 25
-2351.9%
11.0%
Q4 24
-4477.3%
Q3 24
-1698.7%
14.1%
Q2 24
-2104.0%
10.8%
Q1 24
-2616.7%
13.7%
Net Margin
ABSI
ABSI
ICLR
ICLR
Q4 25
-4548.0%
Q3 25
-7594.2%
0.1%
Q2 25
-5155.0%
9.1%
Q1 25
-2234.6%
7.7%
Q4 24
-4358.3%
Q3 24
-1610.7%
9.7%
Q2 24
-1948.8%
6.9%
Q1 24
-2447.1%
9.0%
EPS (diluted)
ABSI
ABSI
ICLR
ICLR
Q4 25
$-0.19
Q3 25
$-0.20
$0.03
Q2 25
$-0.24
$2.30
Q1 25
$-0.21
$1.90
Q4 24
$-0.26
Q3 24
$-0.24
$2.36
Q2 24
$-0.22
$1.76
Q1 24
$-0.22
$2.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABSI
ABSI
ICLR
ICLR
Cash + ST InvestmentsLiquidity on hand
$144.3M
$468.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.4M
$9.3B
Total Assets
$216.3M
$16.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABSI
ABSI
ICLR
ICLR
Q4 25
$144.3M
Q3 25
$152.5M
$468.9M
Q2 25
$38.0M
$390.4M
Q1 25
$47.0M
$526.7M
Q4 24
$112.4M
Q3 24
$38.2M
$695.5M
Q2 24
$42.9M
$506.6M
Q1 24
$58.8M
$396.1M
Total Debt
ABSI
ABSI
ICLR
ICLR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$4.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABSI
ABSI
ICLR
ICLR
Q4 25
$189.4M
Q3 25
$210.3M
$9.3B
Q2 25
$173.4M
$9.6B
Q1 25
$198.8M
$9.5B
Q4 24
$179.1M
Q3 24
$201.3M
$9.8B
Q2 24
$221.5M
$9.6B
Q1 24
$240.1M
$9.4B
Total Assets
ABSI
ABSI
ICLR
ICLR
Q4 25
$216.3M
Q3 25
$245.0M
$16.5B
Q2 25
$209.9M
$16.6B
Q1 25
$232.4M
$16.7B
Q4 24
$213.6M
Q3 24
$235.2M
$17.2B
Q2 24
$255.5M
$17.0B
Q1 24
$274.9M
$17.0B
Debt / Equity
ABSI
ABSI
ICLR
ICLR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.02×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABSI
ABSI
ICLR
ICLR
Operating Cash FlowLast quarter
$-29.2M
$387.6M
Free Cash FlowOCF − Capex
$-29.3M
$333.9M
FCF MarginFCF / Revenue
-4505.4%
16.3%
Capex IntensityCapex / Revenue
15.8%
2.6%
Cash ConversionOCF / Net Profit
164.59×
TTM Free Cash FlowTrailing 4 quarters
$-94.2M
$1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABSI
ABSI
ICLR
ICLR
Q4 25
$-29.2M
Q3 25
$-25.0M
$387.6M
Q2 25
$-16.9M
$146.2M
Q1 25
$-21.8M
$268.2M
Q4 24
$-17.0M
Q3 24
$-20.7M
$402.7M
Q2 24
$-16.8M
$218.6M
Q1 24
$-17.9M
$327.1M
Free Cash Flow
ABSI
ABSI
ICLR
ICLR
Q4 25
$-29.3M
Q3 25
$-26.0M
$333.9M
Q2 25
$-17.1M
$113.9M
Q1 25
$-21.9M
$239.3M
Q4 24
$-17.0M
Q3 24
$-20.8M
$359.3M
Q2 24
$-17.2M
$182.3M
Q1 24
$299.9M
FCF Margin
ABSI
ABSI
ICLR
ICLR
Q4 25
-4505.4%
Q3 25
-6876.5%
16.3%
Q2 25
-2883.0%
5.6%
Q1 25
-1854.5%
12.0%
Q4 24
-2554.4%
Q3 24
-1221.6%
17.7%
Q2 24
-1352.4%
8.6%
Q1 24
14.3%
Capex Intensity
ABSI
ABSI
ICLR
ICLR
Q4 25
15.8%
Q3 25
254.5%
2.6%
Q2 25
37.6%
1.6%
Q1 25
2.1%
1.4%
Q4 24
3.5%
Q3 24
2.8%
2.1%
Q2 24
26.2%
1.7%
Q1 24
0.0%
1.3%
Cash Conversion
ABSI
ABSI
ICLR
ICLR
Q4 25
Q3 25
164.59×
Q2 25
0.80×
Q1 25
1.74×
Q4 24
Q3 24
2.04×
Q2 24
1.49×
Q1 24
1.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABSI
ABSI

Segment breakdown not available.

ICLR
ICLR

Other Customers$681.3M33%
Clients1125$549.4M27%
Clients15$503.3M25%
Clients610$308.8M15%

Related Comparisons